Medifast, Inc. Q3 2025 Earnings Recap

MED Q3 2025 November 4, 2025

Medifast's third-quarter results for 2025 showcased a strategic shift towards a holistic approach to metabolic health, reinforcing its commitment to long-term wellness solutions while navigating changes in the weight loss industry.

Earnings Per Share Miss

$-0.21 vs $-0.01 est.

-2000.0% surprise

Revenue Beat

89409000 vs 71400000 est.

+25.2% surprise

Market Reaction

1-Day +0.84%

5-Day +0.42%

30-Day -7.66%

Key Takeaways

Achieved 16-week clinical results showing clients retained 98% of lean mass and reduced visceral fat by 14%, underscoring the effectiveness of its metabolic health programs.
Expanded insights with 61% of coaches assisting clients using GLP-1 medications, highlighting the integration of medication knowledge into client support.
Announced plans for innovative product launches incorporating next-generation ingredients targeting metabolic enhancement, set to hit the market next year.
Transitioning brand perception from a weight loss company to a broader leader in metabolic health, targeting a more expansive and durable market.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit MED on AllInvestView.